Suppr超能文献

一系列含茚满结构的新型NBTIs的发现及其对多重耐药革兰氏阴性病原菌的抗菌活性研究

Discovery of a Series of Indane-Containing NBTIs with Activity against Multidrug-Resistant Gram-Negative Pathogens.

作者信息

Cumming John G, Kreis Lukas, Kühne Holger, Wermuth Roger, Vercruysse Maarten, Kramer Christian, Rudolph Markus G, Xu Zhiheng

机构信息

Roche Pharma Research & Early Development, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland.

China Innovation Center of Roche, Roche R&D Center (China) Ltd., Shanghai 201203, China.

出版信息

ACS Med Chem Lett. 2023 Jun 22;14(7):993-998. doi: 10.1021/acsmedchemlett.3c00187. eCollection 2023 Jul 13.

Abstract

The rise of multidrug-resistant (MDR) Gram-negative bacteria is a major global health problem necessitating the discovery of new classes of antibiotics. Novel bacterial topoisomerase inhibitors (NBTIs) target the clinically validated bacterial type II topoisomerases with a distinct binding site and mechanism of action to fluoroquinolone antibiotics, thus avoiding cross-resistance to this drug class. Here we report the discovery of a series of NBTIs incorporating a novel indane DNA binding moiety. X-ray cocrystal structures of compounds and bound to DNA gyrase-DNA were determined, revealing specific interactions with the enzyme binding pocket at the GyrA dimer interface and a long-range electrostatic interaction between the basic amine in the linker and the carboxylate of Asp83. Exploration of the structure-activity relationship within the series led to the identification of lead compound , which showed potent broad-spectrum activity against a panel of MDR Gram-negative bacteria.

摘要

多重耐药(MDR)革兰氏阴性菌的出现是一个重大的全球健康问题,需要发现新型抗生素类别。新型细菌拓扑异构酶抑制剂(NBTIs)靶向经临床验证的细菌II型拓扑异构酶,其结合位点和作用机制与氟喹诺酮类抗生素不同,从而避免对该类药物产生交叉耐药性。在此,我们报告了一系列含有新型茚满DNA结合部分的NBTIs的发现。测定了化合物 和 与DNA促旋酶-DNA结合的X射线共晶体结构,揭示了在GyrA二聚体界面与酶结合口袋的特异性相互作用,以及连接子中的碱性胺与Asp83的羧酸盐之间的远程静电相互作用。对该系列化合物构效关系的探索导致了先导化合物 的鉴定,该化合物对一组MDR革兰氏阴性菌显示出强大的广谱活性。

相似文献

1
Discovery of a Series of Indane-Containing NBTIs with Activity against Multidrug-Resistant Gram-Negative Pathogens.
ACS Med Chem Lett. 2023 Jun 22;14(7):993-998. doi: 10.1021/acsmedchemlett.3c00187. eCollection 2023 Jul 13.
2
Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents.
ACS Med Chem Lett. 2014 Mar 12;5(5):609-14. doi: 10.1021/ml500069w. eCollection 2014 May 8.
3
Novel Indane-Containing NBTIs with Potent Anti-Gram-Negative Activity and Minimal hERG Inhibition.
ACS Med Chem Lett. 2023 Nov 10;14(12):1791-1799. doi: 10.1021/acsmedchemlett.3c00422. eCollection 2023 Dec 14.
5
Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors.
PLoS One. 2020 Feb 19;15(2):e0228509. doi: 10.1371/journal.pone.0228509. eCollection 2020.
9
Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs.
Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048223. doi: 10.1128/aac.00482-23. Epub 2023 Sep 19.
10
Dioxane-Linked Amide Derivatives as Novel Bacterial Topoisomerase Inhibitors against Gram-Positive .
ACS Med Chem Lett. 2020 Oct 19;11(12):2446-2454. doi: 10.1021/acsmedchemlett.0c00428. eCollection 2020 Dec 10.

引用本文的文献

1
Structural and Mechanistic Insights into Atypical Bacterial Topoisomerase Inhibitors.
ACS Med Chem Lett. 2025 Apr 1;16(4):660-667. doi: 10.1021/acsmedchemlett.5c00060. eCollection 2025 Apr 10.
3
BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections.
Nat Commun. 2024 Sep 18;15(1):8202. doi: 10.1038/s41467-024-52557-2.
4
Development of Novel Bacterial Topoisomerase Inhibitors Assisted by Computational Screening.
ACS Med Chem Lett. 2024 Jul 15;15(8):1287-1297. doi: 10.1021/acsmedchemlett.4c00162. eCollection 2024 Aug 8.
5
Novel Indane-Containing NBTIs with Potent Anti-Gram-Negative Activity and Minimal hERG Inhibition.
ACS Med Chem Lett. 2023 Nov 10;14(12):1791-1799. doi: 10.1021/acsmedchemlett.3c00422. eCollection 2023 Dec 14.

本文引用的文献

1
A Short History of Topoisomerases at Actelion Pharmaceuticals.
Chimia (Aarau). 2022 Aug 24;76(7-8):647-655. doi: 10.2533/chimia.2022.647.
2
The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV.
J Med Chem. 2022 May 12;65(9):6431-6440. doi: 10.1021/acs.jmedchem.2c00039. Epub 2022 May 3.
3
Discovery of Pyrido[2,3-]indole Derivatives with Gram-Negative Activity Targeting Both DNA Gyrase and Topoisomerase IV.
J Med Chem. 2020 Sep 10;63(17):9623-9649. doi: 10.1021/acs.jmedchem.0c00768. Epub 2020 Aug 24.
4
Two Decades of Successful SAR-Grounded Stories of the Novel Bacterial Topoisomerase Inhibitors (NBTIs).
J Med Chem. 2020 Jun 11;63(11):5664-5674. doi: 10.1021/acs.jmedchem.9b01738. Epub 2020 Feb 17.
6
Machine learning-powered antibiotics phenotypic drug discovery.
Sci Rep. 2019 Mar 21;9(1):5013. doi: 10.1038/s41598-019-39387-9.
7
Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase.
ACS Infect Dis. 2019 Apr 12;5(4):570-581. doi: 10.1021/acsinfecdis.8b00315. Epub 2019 Feb 28.
8
Novel bacterial topoisomerase inhibitors: challenges and perspectives in reducing hERG toxicity.
Future Med Chem. 2018 Oct 1;10(19):2241-2244. doi: 10.4155/fmc-2018-0272. Epub 2018 Sep 14.
9
The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics.
Ann N Y Acad Sci. 2019 Jan;1435(1):18-38. doi: 10.1111/nyas.13598. Epub 2018 Feb 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验